ArticleEFSA journal. European Food Safety Authority2021
Safety evaluation of steviol glycoside preparations, including rebaudioside AM, obtained by enzymatic bioconversion of highly purified stevioside and/or rebaudioside A stevia leaf extracts.
Article in EFSA journal. European Food Safety Authority, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Trial
- Safety evaluation of the food additive rebaudioside M produced via enzymatic conversion of purified steviol glycosides leaf extracts.EFSA journal. European Food Safety Authority · 2026Article
- Raman Spectroscopic Authentication of Rebaudioside M: Discriminating Natural, Fermentation-Derived, and Enzymatically Bioconverted Stevia Sweeteners.Foods (Basel, Switzerland) · 2026Article
- Safety evaluation of the modification of the food additive enzymatically produced steviol glycosides (E 960c).EFSA journal. European Food Safety Authority · 2026Article
- Safety of the proposed amendment of the specifications of the food additive E960c(i) or E960c(ii).EFSA journal. European Food Safety Authority · 2025Article
- Scientific opinion on the extension of the authorisation of use of the food additive steviol glycosides (E 960a-d) and the modification of the acceptable daily intake (ADI) for steviol.EFSA journal. European Food Safety Authority · 2024Article
- Safety evaluation of the food additive steviol glycosides, predominantly Rebaudioside M, produced by fermentation usingEFSA journal. European Food Safety Authority · 2023Article
- Safety of the proposed amendment of the specifications for enzymatically produced steviol glycosides (E 960c): Rebaudioside D produced via enzymatic bioconversion of purified stevia leaf extract.EFSA journal. European Food Safety Authority · 2022Article
- Safety evaluation of glucosylated steviol glycosides as a food additive in different food categories.EFSA journal. European Food Safety Authority · 2022Article
- Safety evaluation of steviol glycoside preparations, including rebaudioside AM, obtained by enzymatic bioconversion of highly purified stevioside and/or rebaudioside A stevia leaf extracts.EFSA journal. European Food Safety Authority · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion on the safety of steviol glycoside preparations, including rebaudioside AM, obtained by enzymatic bioconversion of highly purified stevioside and/or rebaudioside A stevia leaf extracts. These steviol glycoside preparations are produced via enzymatic bioconversion of highly purified stevioside and/or rebaudioside A extracts obtained from stevia plant using two UDP-glucosyltransferases and one sucrose synthase enzymes produced by the genetically modified strains of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.